MARKET

GRAY

GRAY

GRAYBUG VISION, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.160
+0.090
+2.21%
After Hours: 4.100 -0.06 -1.44% 16:08 07/30 EDT
OPEN
4.100
PREV CLOSE
4.070
HIGH
4.160
LOW
4.030
VOLUME
184.98K
TURNOVER
--
52 WEEK HIGH
37.88
52 WEEK LOW
3.430
MARKET CAP
79.69M
P/E (TTM)
-2.3944
1D
5D
1M
3M
1Y
5Y
22 Stocks Moving in Tuesday's Pre-Market Session
Gainers Exela Technologies, Inc. (NASDAQ: XELA) rose 39% to $2.05 in pre-market trading after gaining over 5% on Monday.
Benzinga · 06/29 11:05
61 Biggest Movers From Yesterday
Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its flagship MarinOne platform.
Benzinga · 06/29 08:58
Graybug Vision reaches a three-month high on nearly ten times average volume
Adding more than a quarter of its value today so far, clinical-stage biopharmaceutical company Graybug Vision ([[GRAY]] +26.5%) is on course to record its biggest one-day gain since December. ~19.2M
Seekingalpha · 06/28 18:38
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers
Benzinga · 06/28 16:32
44 Stocks Moving In Monday's Mid-Day Session
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy.
Benzinga · 06/28 16:03
Intellia Therapeutics, Verve Therapeutics leads healthcare gainers; CEL-SCI, Acurx Pharmaceuticals among major losers
Gainers: Intellia Therapeutics (NTLA) +39%, Verve Therapeutics (VERV) +29%, Graybug Vision (GRAY) +24%, Anavex Life Sciences (AVXL) +15%, ReShape Lifesciences (RSLS) +13%.Losers: CEL-SCI (CVM) -38%, Acurx Pharmaceuticals (ACXP) -22%, Exelixis (EXEL) -20%, ...
Seekingalpha · 06/28 15:04
58 Biggest Movers From Friday
Gainers CAI International, Inc. (NYSE: CAI) shares surged 46.9% to close at $56.05 on Friday after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc.
Benzinga · 06/21 08:40
50 Biggest Movers From Yesterday
Gainers Verve Therapeutics, Inc. (NASDAQ: VERV) shares surged 68% to settle at $31.92 on Thursday after the company priced its IPO at $19 per share.
Benzinga · 06/18 09:03
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GRAY. Analyze the recent business situations of GRAYBUG VISION, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GRAY stock price target is 4.750 with a high estimate of 6.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 50
Institutional Holdings: 13.11M
% Owned: 68.46%
Shares Outstanding: 19.16M
TypeInstitutionsShares
Increased
14
1.27M
New
23
1.47M
Decreased
8
2.70M
Sold Out
6
2.01M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.07%
Pharmaceuticals & Medical Research
-0.24%
Key Executives
Non-Executive Chairman/Independent Director
Christy Shaffer
President/Chief Executive Officer/Director
Frederic Guerard
Chief Financial Officer
Robert Breuil
Chief Technology Officer
Daniel Salain
Other
Parisa Zamiri
Independent Director
Christina Ackermann
Independent Director
Eric Bjerkholt
Independent Director
Gerald Cagle
Independent Director
Julie Eastland
No Data
About GRAY
Graybug Vision, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. Its lead product candidate, GB-102, is an intravitreal injection of a microparticle depot formulation of sunitinib, an inhibitor of neovascular growth and permeability, which are causes of retinal disease. It is developing GB-102 as a once-every-six months intravitreal injection for the treatment of wet age-related macular degeneration or wet (AMD), and diabetic macular edema (DME). It is also using its technologies to develop GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy (DR), as well as GB-401, an intravitreally injectable depot formulation of a beta-adrenergic blocking agent prodrug with a dosing regimen of once every six months or longer for the treatment of primary open-angle glaucoma (POAG).

Webull offers kinds of Graybug Vision Inc stock information, including NASDAQ:GRAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRAY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GRAY stock methods without spending real money on the virtual paper trading platform.